This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about Myeloid cell nuclear differentiation antigen.
Stimulates the DNA binding of the transcriptional repressor protein YY1. .
Human | |
---|---|
Gene Name: | MNDA |
Uniprot: | P41218 |
Entrez: | 4332 |
Belongs to: |
---|
No superfamily |
myeloid cell nuclear differentiation antigen; PYHIN3
Mass (kDA):
45.836 kDA
Human | |
---|---|
Location: | 1q23.1 |
Sequence: | 1; NC_000001.11 (158831351..158849502) |
Expressed constitutively in cells of the myeloid lineage. Found in promyelocyte stage cells as well as in all other stage cells including peripheral blood monocytes and granulocytes. Also appear in myeloblast cells in some cases of acute myeloid Leukemia.
Nucleus. Cytoplasm. Uniformly distributed throughout the interphase cell nucleus. Associates with chromatin.
You might not think of biotechnology as a company that can cure a disease. But Steven Boster is an exception to the rule. This company has a long track record of developing biotech services and products. Boster, who is known as "he that converts science in a lavatory," is an example of such a company. He has created hundreds of primary antibodies, numerous immunohistochemistry products, as well as one of the largest Chinese antibody catalogs by the late 1990s. PicoKine(tm), Boster’s latest innovation, is a proprietary ELISA-platform called PicoKine. This unique platform utilizes proprietary trade secrets to deliver high-sensitivity ELISA kits.
The Journal of Clinical Investigation published a study that outlined the best uses of MNDA markers. To detect the protein, researchers used primary antibody. These include rabbit polyclonal antibodies against-calbindin, mouse anti-GFAP and anti-TGN38, GluR1 and mouse anti-GFAP antibodies. Further research is necessary to determine the best possible uses of the MNDA indicator.
Novartis approved Kymriah's MNDA mark. The approval will be conditional on the verification of its clinical benefits in confirmatory studies. FDA approval has been given to the company for the drug candidates in three indications. Kymriah CAR-T cells therapy is the only one approved in both the pediatric as well as adult settings. Its approval is the latest in a long line of developments aimed at treating diseases caused by glioma.
Novartis provided personal travel reimbursements, honoraria, and fees for this project to IK and LA. RM is an advisory panel member of Viela Bio/Horizon Therapeutics. Novartis provides research support and speaker honoraria to him. Biogen, Merck and Sanofi Genzyme have also paid him personal fees. CFT is a member in good standing of the Novartis neuro-ophthtalmology advisory board.
As a result, his role on the scientific advisory board of Alexion is a non-competing role. His financial support comes from honoraria from Bayer (Chugai), Biogen Idec/GmbH and Genzyme. He also accepts honoraria for Novartis and serves as a member on the steering committee of MedImmune, Kael-GemVax.
The MNDA marker, a gene that has been linked to a variety diseases, includes chronic lymphocytic lymphoma and mantle-cell Lymphoma. It is especially useful in diagnosing NMZL, a type of lymphoma that is derived from the marginal zone. It can also help distinguish NMZL and FL, a type leukemia that is derived from the marginal zone.
PMID: 1644857 by Briggs J.A., et al. Cloning and expression of the human myeloid cell nuclear differentiation antigen: regulation by interferon alpha.
PMID: 1377701 by Burrus G.R., et al. Characterization of the human myeloid cell nuclear differentiation antigen: relationship to interferon-inducible proteins.